OSC Co-culture for Rescue IVM of Human GV Oocytes (OSC-rIVM)
Effect of iPSC-Derived Ovarian Support Cell Co-culture on Rescue In Vitro Maturation of Human Germinal Vesicle Oocytes: A Randomized Sibling-Oocyte Controlled Trial
Aperçu de l'étude
Statut
Les conditions
Description détaillée
Immature human oocytes at the germinal vesicle (GV) stage retrieved during routine IVF cycles are usually not used in standard clinical treatment. Rescue in vitro maturation (r-IVM) offers a potential strategy to increase the number of mature oocytes available for laboratory use, but maturation outcomes for GV oocytes remain limited. This study investigates whether co-culture with iPSC-derived ovarian support cells (OSCs) can improve the biological performance of r-IVM in surplus GV oocytes.
This is a single-center, randomized, sibling-oocyte controlled study conducted at the Infertility Department of Hung Vuong Hospital, Ho Chi Minh City, Vietnam. Women undergoing routine IVF who have at least two eligible GV oocytes in one retrieval cycle may participate after providing informed consent. Within each participant, eligible GV oocytes are allocated in a 1:1 ratio to either conventional r-IVM in CSCMC medium or r-IVM in CSCMC medium with iPSC-derived OSC co-culture.
Allocation is performed separately within each participant using a manual lottery-based randomization procedure. If an odd number of eligible GV oocytes is available, one oocyte is randomly excluded before allocation to preserve equal within-participant assignment. Oocytes in both groups are cultured under identical laboratory conditions; the only difference between groups is the presence of OSCs in the intervention arm. Matured oocytes are assessed after 24 hours. Oocytes reaching MII undergo ICSI, and fertilized oocytes are cultured to day 5-6 in a time-lapse system. Embryo development is evaluated using standard morphology criteria with independent assessment and time-lapse support.
The study is designed to compare biological outcomes between conventional r-IVM and OSC-supported r-IVM while minimizing between-patient confounding through within-participant allocation. The participant is treated as the clustering unit for statistical analysis.
This section is taken from the protocol's rationale, procedures, randomization logic, and outcome plan.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Huy Phuong Tran, PhD
- Numéro de téléphone: +84 896 416 098
- E-mail: tranphuonghuy1994@gmail.com
Lieux d'étude
-
-
-
Ho Chi Minh City, Viêt Nam, 700000
- Infertility Department
-
Contact:
- Huy Phuong Tran, PhD
- Numéro de téléphone: +84 896 416 098
- E-mail: tranphuonghuy1994@gmail.com
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
Accepte les volontaires sains
La description
Inclusion Criteria:
- Women aged 18 to 45 years.
- At least 2 GV oocytes retrieved in a single oocyte retrieval cycle.
- Voluntary informed consent from the couple to participate in the study.
- Agreement that all embryos generated from the study will be used for research purposes only and will not be transferred for clinical treatment.
Exclusion Criteria:
- Sperm obtained through surgical retrieval procedures, including PESA, MESA, TESE, or micro-TESE.
- Use of donor gametes, including donor oocytes or donor sperm.
- Participants with GV oocytes showing obvious morphological abnormalities, such as degeneration, severe deformation, or marked cytoplasmic abnormalities.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Science basique
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: Conventional r-IVM
Eligible GV oocytes are cultured for 24 hours in standard CSCMC medium under routine rescue in vitro maturation conditions without ovarian support cell co-culture.
|
Standard rescue in vitro maturation of denuded germinal vesicle oocytes in CSCMC culture medium for 24 hours under routine IVF laboratory conditions.
|
|
Expérimental: r-IVM with iPSC-Derived OSC Co-culture
Eligible GV oocytes are cultured for 24 hours in CSCMC medium with co-culture using iPSC-derived ovarian support cells prepared according to laboratory SOPs.
|
Rescue in vitro maturation of denuded germinal vesicle oocytes in CSCMC culture medium for 24 hours with co-culture using iPSC-derived ovarian support cells supplied by Dioseve Inc. and prepared according to the laboratory SOP.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
MII maturation rate after 24 hours of culture
Délai: 24 hours after initiation of culture
|
Proportion of cultured GV oocytes that reach metaphase II (MII) after 24 hours of rescue in vitro maturation.
|
24 hours after initiation of culture
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Fertilization rate
Délai: 17 to 19 hours after ICSI
|
Proportion of injected oocytes showing normal fertilization with two pronuclei (2PN).
|
17 to 19 hours after ICSI
|
|
Day 3 embryo formation rate
Délai: Day 3 after fertilization
|
Proportion of normally fertilized oocytes that develop to cleavage-stage embryos by day 3.
|
Day 3 after fertilization
|
|
Good-quality day 3 embryo rate
Délai: Day 3 after fertilization
|
Proportion of day 3 embryos meeting predefined good-quality criteria.
|
Day 3 after fertilization
|
|
Blastocyst formation rate
Délai: Day 5 to Day 6 after fertilization
|
Proportion of normally fertilized oocytes that develop to the blastocyst stage by day 5 or day 6.
|
Day 5 to Day 6 after fertilization
|
|
Good-quality blastocyst rate
Délai: Day 5 to Day 6 after fertilization
|
Proportion of blastocysts meeting predefined good-quality criteria.
|
Day 5 to Day 6 after fertilization
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Tuyet Thi-Diem Hoang, MD, Hung Vuong Hospital
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- CS/HV/26/04
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .